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Pathologists have an important role in the diagnosis of infec-
tious disease (ID). In many cases, a definitive diagnosis can be
made using cytopathology alone. However, several ancillary
techniques can be used on cytological material to reach a spe-
cific diagnosis by identifying the causative agent and conse-
quently defining the management of the patient. This review
aims to present the effectiveness of the application of molecular
studies on cytological material to diagnose IDs and discuss the
advantages and disadvantages of the various molecular techni-
ques according to the type of cytological specimen and the
infectious agents. Diagn. Cytopathol. 2016;44:156–164. VC 2015
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Infectious diseases (ID) are well-acknowledged threats to
global human health in the past and at present. Since the
first report of Grieg and Gray in 1904,1 that stated “the
potential of fine-needle aspiration (FNA) in the diagnosis
of ID,” the role of cytopathology in ID has expanded
enormously with the advances in molecular techniques.
Cytopathologists are frequently the first to diagnose an
ID, and cytopathology material can be used to follow the
disease and monitor the response to the treatment. How-
ever, the diagnosis of ID and the specific causative agent
based solely on the cytomorphology and traditional ancil-
lary techniques has limitations and needs to be correlated
with additional techniques including molecular methods.
The integration of molecular methods into the diagno-
sis of ID using cytology material requires educated per-
sonnel, facilities and set work flow designs, but most
importantly the methods have to be standardized and per-
formed in collaboration with a clinical microbiologist. It
has been shown that costs will be reduced in the long-
term by the use of molecular methods compared with
conventional methods in the diagnosis of ID: patient out-
come are improved, costs are reduced by the use of cor-
rect antimicrobials, and hospital stay times will be
shortened reducing nosocomial infections.2
In the literature, studies have focused on the diagnosis
of granulomatous diseases using molecular methods on
cytology specimens. This review contains comprehensive,
up to date, and systematic information covering the use
of molecular techniques to diagnose ID in gynecological
and non-gynecological cytological material.
Molecular Methods
Molecular diagnostics of IDs are based particularly on
nucleic acid assay methods. There are three main
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categories of nucleic acid test: amplified, non-amplified,
and microarrays.
Amplified Nucleic Acid Techniques
Amplified DNA based methods are composed of three
subcategories as target, signal, and probe amplification.
The polymerase chain reaction (PCR) amplification- and
hybridization-based approaches are the most widely used
ones in amplified techniques (Fig. 1).3–5 Target amplifica-
tion methods utilize post-amplification analysis where
required.
PCR is the most common target amplification method
to detect cultured and uncultured bacteria used currently
in clinical practice.6 Since 1985 many PCR amplification
based techniques have been designed for bacterial detec-
tion and identification, including: competitive PCR, most-
probable number PCR (MPN-PCR), co-operational PCR,
BIO-PCR, nested-PCR, and real-time PCR. Real-time
PCR is the most useful and commonly used method
because it is faster, has lower contamination risk and
higher sensitivity, and has quantitative applications. PCR
analysis can be applied directly to fresh material obtained
from FNA, to liquid-based cytology materials and even to
cells scraped from slides.7 DNA is amplified by repeating
three major steps, which are denaturation of the DNA
template, annealing of oligonucleotide primers, and exten-
sion of the primers by DNA polymerase, to produce a
copy of the target gene.3 To yield high quality DNA is
definitely the most critical step.
Unlike PCR, transcription based methods (TBM) and
strand displacement amplification (SDA) are isothermal
techniques that do not require a thermal cycler.8 Nucleic
acid sequence-based amplification (NASBA) and
transcription-mediated amplification (TMA) are TBM in
which the RNA target is reverse transcribed into cDNA
and then RNA copies are synthesized with a RNA poly-
merase. Both TBM and SDA have been used particularly
for sexually transmitted diseases (e.g., Chlamydia tracho-
matis and Neisseria gonorrheae), although false-positive
results with this technique have been reported in the
literature.8,9
Signal amplification assays are correlated with the
amount of the target sequence in the cytological material.4,8
bDNA assays usually are used to detect HCV, HBV, and
HIV-1 blood levels and are based on the balance between
capture probe bDNA assays and the quantitation of the
microorganism.3,8 Loop-mediated isothermal amplification
(LAMP) is a one-step technique which is very similar to
SDA and has been developed for cytomegalovirus (CMV),
herpes simplex virus (HSV), varicella zoster virus (VZV),
BK virus, and human papillomavirus (HPV).8
In the last two decades, hybrid capture has become a
popular technique applicable to gynecological cytology
specimens. Briefly, the method entails the reaction
between DNA–RNA hybrids and anti-hybrid antibodies,
with a luminometer measuring the light emitted.3,8 Chla-
mydia trachomatis, Neisseria gonorrheae, CMV, and par-
ticularly HPV are the common agents detected by this
method.3
The most important benefit of amplification methods is
the requirement for low target copy numbers within a
direct specimen. On the other hand, contamination is the
main problem of the amplified techniques when compared
with microarrays and non-amplified methods.3,10 Also, the
evaluation of the sensitivity of each specimen type and the
setting up of a number of positive and negative controls
for each diagnostic run are vital for rendering standardiza-
tion, which is sine qua non for molecular studies.11,12
Microarrays
Microarrays, multiplex nucleic acid amplification techniques,
and mass spectrometry are multiparameter assay techniques
that provides rapid diagnoses with a decreased contamina-
tion risk, low cost, high sensitivity/specificity, and rapid
kinetics through the use of a closed-tube systems.5,8
Non-Amplified Nucleic Acid Techniques
The well-known format is probe hybridization comprised
of liquid phase, solid phase, and in situ hybridization.
Different species can be detected by in-situ hybridization
in the one clinical sample in the same run through use of
multiple probes labeled with different fluorescent dyes.9 It
is a very commonly used and rapid technique with the
four “S” advantages: safe, simple, specific, and sensitive
in detecting and identifying the microorganisms directly
from the clinical specimen such as a smear. The presence
of unbound probes and the nonspecific binding of the
probe to non-target microorganisms may give false results
with this technique.9
Fig. 1. Nucleic acid testing techniques. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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Applications in Non-Gynecological Cytology
Exfoliative Cytology
Bronchoalveolar Lavage and Sputum. Community
acquired pneumonia (CAP) is the major cause of death
due to ID in the United States and worldwide.13 Due to
the high contamination risk of upper airway flora, cytol-
ogy specimens may show diagnostic limitations. As the
most common agent of CAP, Streptococcus pneumonia is
a fastidious bacterium which needs special environmental
and nutritional conditions to culture, and so molecular
methods are recommended for its detection. The concen-
tration of the bacteria in the cytological specimen is a
significant step in deciding whether it is a pathogen and
which is the appropriate molecular method to diagnose
the CAP. Streptococcus pneumoniae, Mycoplasma pneu-
monia, Staphylococcus aureus, and Chlamydia pneumo-
niae among others, should be detected at a certain
concentration before they are considered a pathogen.
However, even trace amounts of Mycobacterium tubercu-
losis, Bacillus anthracis, Legionella, endemic fungi, Yer-
sinia pestis, and Francisella tularensis are assumed
pathogenic regardless of the concentration. Real-time
PCR is the best method for use in this situation because
is also quantitative.
Invasive aspergillosis (IA) is a significant cause of
death in cancer patients. The concentration threshold is
also important in the diagnosis of aspergillosis, and a
quantitative PCR (real-time PCR) is recommended to dif-
ferentiate colonization from infection. Sun et al. reported
the sensitivity of 95% and specificity of 95% in the diag-
nosis of Aspergillus species with PCR.14
Paracoccidioides brasiliensis can cause a systemic
mycosis agent that is not limited to immune-compromised
patients. It is only seen in Latin America and is accepted
as endemic particularly in Brasil. Histoplasma spp. and
Coccidioides immitis can be misinterpreted as paracocci-
dioidomycosis. LAMP was suggested as a highly specific
and sensitive method to identify the target P. brasiliensis
P43 gene in sputa.15–17 Coccidioides immitis and Blasto-
myces dermatitidis are other examples of systemic fungal
infections that can be misdiagnosed clinically and mor-
phologically, and specifically diagnosed on DNA probes
specific for unique RNA sequences.
Mycobacterium africanum and M. canetti mainly seen
in African countries cause human tuberculosis and share
almost identical genomes, called “the mycobacterium
tuberculosis complex organisms” (MTC), along with
Mycobacterium tuberculosis and Mycobacterium bovis
which are the most common members of this group in all
developing countries. However, it is almost impossible to
differentiate these mycobacteria using conventional meth-
ods. Mycobacterium bovis is an increasing threat particu-
larly in Asia, Latin America and the HIV-infected patient
group and can cause pulmonary and extrapulmonary
tuberculosis in humans.18 Bakshi et al. showed that it is
possible to distinguish M. bovis from M. tuberculosis
using a multiplex PCR based on the absence of a 12.7 kb
fragment in M. bovis which is present in M. tuberculo-
sis.18 Chen et al. using the microsphere based multiplex
assay in human sputum reported high identification rates
to separate M. tuberculosis and M. bovis species, 98.9%
and 91.9%, respectively.19 Neonakis et al. detected M.
tuberculosis with 88.2% sensitivity and 99% specificity
by using LAMP in clinical specimens. As in the study of
Iwamoto et al. and Aryan et al. LAMP has been estab-
lished as a sensitive, rapid, and low-cost method for typi-
cal and atypical mycobacteria including M. tuberculosis
and M. bovis (including M. bovis BCG), and the less
common species M. africanum, M. microti, M. canetti, M.
caprae, and M. pinnipedii in clinical samples.20–22 There
are other applications of real-time PCR to detect infec-
tious agents in respiratory cytological samples that are
discussed further in the section on FNA.
Effusions. Chronic pericardial or pleural non-malignant
effusions need to be analyzed for possible infection, the
most common of which is tuberculosis. The benefits of
PCR and usefulness of DNA PCR in diagnosing tubercu-
losis are well documented in the literature.23,24
Urine. BKV and John Cunningham virus (JCV) are the
human polyoma viruses that are responsible of primary
infection in almost 80% of the healthy population. After a
latency period in the genitourinary tract including kid-
neys, viruses may be reactivated in immunodeficiency
conditions such as HIV-infected or kidney transplant
patients. Specific cytomorphologic findings, including
Decoy cells, may be seen in 4% of urine samples. The
studies based on PCR and particularly nested-PCR (diag-
nostic accuracy 56%) from urine specimens were reported
as the most sensitive methods to detect polyomavirus
infections and identify as the causative agent BKV or
JCV.25–27
Cerebrospinal Fluid (CSF). PCR, NASBA, and DNA
branched assays have been used successfully to detect
both RNA and DNA viruses in CSF for diagnosing viral
encephalitis. The sensitivity of these techniques depends
on the amount of the CSF sample ranging from 30 to
100–200 mL. Real time and nested PCR have high utility
with the various primers for pan-herpesvirus assays in the
detection of HSV-1, HSV-2, VZV, CMV and Epstein–Barr
virus (EBV), and human herpesvirus-6 (HHV-6) in various
combinations.28–30 These assays are proven as clinically
useful in the assessment of HIV patients presenting with
a CNS disease, since multiple herpes viruses are capable
of causing neurologic symptoms in this subset of patients.
HSV-1 and 22, EBV, and VZV are the most common
agents of sporadic viral encephalitis and Multiplex PCR
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assays may be the best method to detect these agents in a
single CSF specimen.28
Fine-Needle Aspiration Cytology (FNAC)
Lymph Node. It is commonly assumed that M. tubercu-
losis is the commonest cause of lymphadenitis, but PCR
studies have shown that Bartonella henselae is the most
common agent in both adults and children, presenting
mostly as Cat Scratch Disease (CSD), although this is
dependent on the population studied.31 Avidor et al.
showed that FNAC specimens for cytologic evaluation
and PCR testing has a 94% sensitivity for the diagnosis
of CSD, while culture, Warthin Starry silver impregnation
stain and other stains offer low sensitivity.32 Fenollar
et al. emphasized that sequencing and hybridization tech-
niques particularly are successful in identifying the spe-
cies of Bartonella infection with visceral involvement
such as bacillary angiomatosis, peliosis hepatitis, and
CSD.6
Extrapulmonary tuberculosis (EPTBC) is a widespread
form of tuberculosis and most commonly presents in head
and neck lymph nodes. FNAC is the first choice for the
diagnosis, but early in the infection and in the absence of
typical granulomas and or caseous necrosis and the fre-
quent absence of acid fast bacilli the diagnosis may not
be able to be made, and the distinction from other granu-
lomatous entities including atypical mycobacteria on mor-
phology alone may not be possible. Even the classical
cytomorphology of EPTBC has lower sensitivity or speci-
ficity with FNAC associated with the traditional methods.
The sensitivity of the Ziehl–Neelsen stain is reported as
20% up to 43% for diagnosing and monitoring the treat-
ment of EPTBC.33 Culture is regarded as the “gold stand-
ard” but needs 6–12 weeks and should be performed in a
biosafety level 3 faculty.34 Unfortunately, time is the
most important factor in the diagnosis of an ID, particu-
larly in immunocompromised conditions such as AIDS.
In the study of Goel et al. nucleic acid testing (NAA)
positivity for mycobacterial infection was reported in
72%–73% in fresh aspirates, regardless of the presence or
absence of AFB.34 Based on the study of Pruhit et al.
PCR provided high sensitivity, specificity, and positive
and negative predictive values (85%, 95%, 96%, and
59%, respectively) by using unstained air-dried cytology
smears in 98 cases for the early and specific diagnosis of
EPTBC. In the same study, Ziehl–Neelsen stain and cul-
ture was able to detect mycobacteria in 15.3%–24.4% of
cases.35 Due to the differences in treatment of typical,
atypical mycobacteriosis, and the other granulomatous
conditions, it is crucial to detect and identify bacteria
with a high diagnostic accuracy.
Toxoplasma gondii may cause a suppurative lymphade-
nitis localized in posterior cervical lymph nodes. FNAC
is very useful to distinguish this infection from malignant
lymphoma and PCR can identify the protozoon.
Biological and clinical differences between HPV-
related and HPV non-related head and neck squamous
cell carcinoma (HNSCC) effect the target therapy,
response, and or resistance to the therapy as well as the
prognosis. Differentiating HPV related from non-related
SCC based solely on morphology is impossible and the
molecular test has become best practice over the past few
years.36,37 HPV16 is the commonest serotype found in
75%–92% of HPV-related HNSCC. Methods for detecting
HPV use different targets such as, HPV DNA, HPV
RNA, E6 E7 viral oncoproteins, and P16 as cellular pro-
tein. PCR based amplifications and DNA in situ hybrid-
izations are used routinely, and the latter is very practical
and allows visualization of the cells with high risk (HR)
HPV DNA making the method highly specific. On the
other hand, PCR based amplification methods (discussed
in the gynecology part of this review) are much more
sensitive and specific, but less practical. Although PCR,
DNA in situ hybridization, and hybrid capture II and the
Cervista technique (able to detect 14 sero-types) show
variability in sensitivity and specificity, these methods
have been successfully used to detect HR HPV in cyto-
logical material, even in the necrosis found in FNA mate-
rial of Head and Neck metastases.36–39 In the prospective
study of Baldassari et al. HR-HPV detection-genotyping
performed on the FNA material from metastatic SCC in
lymph nodes using the Roche Cobas 4800 system showed
a sensitivity of 90% which is greater than studies using
hybrid capture II and the Cervista technique which usu-
ally give high specificity but low sensitivity.40
Lung. The opportunistic infections in immune compro-
mised patients including HIV positive, cancer, and post-
transplant patients, may mimic lung malignancies. Pneu-
mocystis jiroveci is a major pathogen and can involve
extrapulmonary sites including liver, spleen, skin, and
pleural effusions. Specific diagnosis is based mainly on
respiratory cytology materials. Bronchiolo-alveolar lavage
(BAL) has a diagnostic yield of 97%–100%, superior to
sputum with a specificity of 100% and sensitivity of 55%
in the diagnosis of P. jiroveci.41 Invasive procedures such
as BAL and transthoracic FNAC may yield better diagno-
ses. Quantitative PCR (RT-PCR) and nested PCR are the
widespread techniques now used in the diagnosis of pneu-
mocystis pneumonia, and RT-PCR can differentiate colo-
nization from infection in non-HIV patients. Both
techniques have shown high specificity and sensitivity
rates in many articles.42–44
Histoplasma capsulatum, Cryptococcus neoformans,
and Cryptococcus gattii may cause cavitating or solid
lesions often large in size that can be misdiagnosed is
lung malignancies. Mycobacterial infection (tuberculosis)
of respiratory samples may be heralded by finding
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granulomatous inflammation with or without necrosis.
FNA material is suitable for both traditional and molecu-
lar diagnostic methods. A combination of acid fast stain
with PCR has high sensitivity (84%) and specificity
(100%).41 Many studies have focused particularly on real-
time and nested-PCR and sputum and BAL samples a
well as FNA.45,46 Viral pulmonary infections, such as
CMV, Respiratory Syncytial Virus, and Herpes simplex,
can also be confirmed using molecular tests on cytologi-
cal samples.
Skin. Buruli ulcer is an ID of skin presenting with a
painless nodule, a firm plaque or an edematous lesion in
children aged 15 years or younger and is caused by
Mycobacterium ulcerans. It is common in over 30 coun-
tries worldwide, particularly humid tropical areas in West
Africa.47
Edyani et al. proved that FNAC is an effective diag-
nostic tool using the PCR technique, and that higher diag-
nostic accuracy was achieved using samples from non-
ulcerated compared with ulcerated lesions.48 The applica-
tion of PCR to the FNAC samples utilizing 21-gauge nee-
dles yielded 86% sensitivity compared with culture with
44% and microscopy with 26% as demonstrated by Phil-
lips et al.47
Real-time PCR has been suggested for detection, quan-
tification and identification of Leishmania species in clini-
cal samples.49 Traditional methods yield 17% positivity
in the patients with mucosal leishmaniasis while PCR
achieved 71% positivity in the study of Tavares.49
Applications in Gynecological Cytology
The introduction of liquid-based cytology (LBC) in rou-
tine gynecological cytology produced better quality prepa-
rations for cytomorphology and the potential to perform
complementary molecular assessment on residual mate-
rial, particularly molecular tests for HR-HPV detection in
cervical cancer prevention programs. The HR-HPV test
increases the sensitivity of the “Pap test,” and can achieve
an acceptable specificity when used alone.50
HPV Test and Cervical Cancer Screening
The introduction of HPV test for primary cervical cancer
screening has been contentious, but recent studies suggest
that HPV tests can be used for this purpose.51 The
rational that supports the use of HPV testing in cervical
cancer prevention is that the presence of HPV is neces-
sary for cervical cancer development,52 and therefore a
negative HPV test excludes the development of high-
grade lesions. The age to start HPV test screening has
been debated but it should be set so as to avoid unneces-
sary tests while still reaching acceptable levels in detect-
ing CIN2 lesions. Women aged 30 year’s benefit the
most with HPV-based screening. It is also critical to vali-
date the HPV tests considered for use, which must have a
sensitivity for CIN2detection equal or 90% and a speci-
ficity not <98%.53
A plethora of HPV tests have been developed in recent
years, and choice of a specific test depends on a number
of requisites that range from high performance indexes, to
the workload capacity, local commercial concerns and to
equipment maintenance, logistical issues, training, and
cost. The majority of the tests target DNA as does the
doyen Hybrid Capture technology; while others target
RNA, for example, the NorChip PreTect HPV-Proofer.
The important issue, however, is to identify hrHPV with
high clinical sensitivity and acceptable specificity. Cuzick
and colleagues54 compared the performance of six hrHPV
tests commercially available: Hybrid Capture 2 (Qiagen,
Germany), Cobas 4800 HPV Test (Roche, The United
States), Abbot RealTime High Risk HPV Assay (Abbot,
Germany), BD HPV Test (BD Diagnostic, The United
States), PreTect HPV-Proofer (NorChip, Norway), and
APTIMA (Gen-Probe, The United States). Details on the
HPV tests system are depicted in Table I. The authors
Table I. Details of Most Frequently Used Commercially Available Tests for HPV Identification
Test Origin Target Characteristics
Hybrid Capture 2 Qiagen, Hilden, Germany DNA 13 hrHPV types (Hybrid DNA:RNA): 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68
Cobas 4800 HPV Test Roche, Pleasanton, The United States DNA 14 hrHPV types (PCR technology) and HPV16 and HPV 18
identification, distinctly; and 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68
Abbot HPV Assay Abbot, Weisbaden, Germany DNA Two hrHPV types individually (RT PCR): 16, and 18; and also
12 high risk genotypes: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, 68
BD HPV Test BD, Sparks, The United States DNA Six hrHPV types individually (RT PCR): 16, 18, 45, 31, 51 and
52 and three groups of hrHPV: 33 and 58; 35, 39, and 68; and
56, 59 and 66.
PreTect HPV-Proofer Hologic, Klokkarstua, Norway RNA E6/E7 mRNA-based test for oncogenic types 16, 18, 31, 33, and
45.
APTIMA Gen-Probe Incorporated,
San Diego, The United States
RNA E6/E7 mRNA of 14 high-risk HPV types: 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, and 68; with HPV 16 and 18/45
genotyping.
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summarized these six HPV assay methods and observed
the following sensitivity, specificity, and PPV for CIN2
results tests for HC2 as 97.5%, 85.4%, and 4.3%, Cobas
HPV as 97.5%, 84.5%, and 4.1 and APTIMA HPV as
97.5%, 90.2%, and 6.3%.54 Recently, Nolte et al.
designed a comparison study of performance characteris-
tics of Aptima and Cervista HPV tests: Aptima HPV test
was found to be as Cervista, however, specificity was
higher compare to Cervista in the detection of hrHPV in
cervical cytology specimens.55
Most studies have shown that the RNA based assay
APTIMA system has high specificity and sensitivity com-
pared with the other assays.56
The performance of the DNA-based assays was quite
similar with a slightly lower positivity rate for the Abbott
system in the group of women who had tested negative in
the Pap test. Both RNA-based tests had lower performan-
ces in HPV detection in comparison with the DNA tests,
but NorChip had significantly lower performance even
when compared with the APTIMA test. All cases catego-
rized as CIN3 were positive in all tests, with the excep-
tion of one case which tested negative in the Abbott
assay and five negative in the NorChip test.54 However,
the main aim is to show not only transient infections
which in most cases are self-limited but also integrated
hrHPV viral infections which lead to squamous dysplasia
and neoplasia.56 APTIMA demonstrates the overexpres-
sion with the E6 and E7 mRNA of hrHPV. The viral
genes E6 and E7 may inactivate tumor suppressor genes
(P53 and pRB) during the integration into the host
genome and activate the carcinogenesis process.57 In
Sauter et al. the authors reported 21% and 90% decreased
colposcopy referral and QNS (quantity not sufficient)
rates, respectively, with APTIMA compared with HC2.56
APTIMA is the most well-known RNA based detection
assay that detects the 16 hrHPV subtypes but cannot dif-
ferentiate specifically between them,56 and the clinical
evaluation of APTIMA HPV RNA (CLEAR) trial showed
other limitations including cross-reactivity with the low-
risk HPV subtypes 26, 67, 70, 82, and cross-
contamination of samples58 (US Food and DrugAdminis-
tration. APTIMAVR HPV Assay Labeling. accessdata.f-
da.gov/cdrh_docs/pdf10/P100042c.pdf. Accessed January
22, 2014).
DNA-based assays include HC2, Cervista, and Cobas.
HC2 and Cervista utilize signal amplification methods. A
large amount of important data on HC2 was collected in
the ALTS study (atypical squamous cells of undetermined
significance [ASCUS]/low-grade squamous intraepithelial
lesion [LSIL] Triage Study).59 However, HC2 does not
have an internal control and may show cross-reaction
with some low risk HPV subtypes representing limitations
despite its high clinical sensitivity.58 Cervista uses the
“Invader chemistry” (Hologic) and targets the HPV L1
gene. Cervista has an internal control with the patient
specimen, but some studies have shown that it has dis-
tinctive limitations during processing with the glacial ace-
tic acid.60 Cobas is a PCR amplification test studied in
47,000 women in the ATHENA trial (Addressing the
Need for Advanced HPV Diagnostics) which demon-
strated excellent performance.61 The U.S. Food and Drug
Administration62 approved the Cobas 4,800 HPV Test for
use in primary screening in women 25 years. As the
first prospective U.S. screening study, the ATHENA63
end-results have very recently been published and it has
been incorporated into current guidelines (http://dx.doi.
org/10.1016/j.ygyno.2014.11.076.). This recommendation
is important because this is a paradigm change for cervi-
cal cancer prevention. The adoption of molecular testing
for primary cervical cancer screening has been seriously
considered by many public authorities in European Coun-
tries,64,65 where cytology-based screening has been suc-
cessfully implemented.
Larsson et al. performed the extended genotyping
approach with Anyplex II HPV28, which detects 28 geno-
types and the human gene beta-globulin HBB in two mul-
tiplex reactions, and CLART HPV2 (Genomica), which
detects 35 genotypes and the human gene CTFR in one
reaction targeting the L1 region of the virus, using
archival clinical samples and found both were suitable
alternative methods even in the presence of minor intra-
assay differences.66
Table II. Details of Most Frequently Used Commercially Available Tests for Other Genital Microorganisms
Test Origin Target Characteristics
COBAS
VR
AMPLICOR
(CT/NG) Tes
Roche, Pleasanton,
The United States
DNA PCR amplification technique for the detection of Chlamydia trachomatis
and/or Neisseria gonorrhoeae
BD ProbeTec ET BD, Sparks, The United States DNA Strand Displacement Amplification (SDA) technology for C. trachoma-
tis, N. gonorrhoeae, or both.
Qiagen HC2 CT/GC
DNA Test
Qiagen, Hilden, Germany DNA Chemiluminescent signal-amplified nucleic acid hybridization for Chla-
mydia trachomatis and/or Neisseria gonorrhoeae
Abbott RealTime
CT/NG assay
Abbot, Weisbaden, Germany DNA Real-time PCR Chlamydia trachomatis and/or Neisseria gonorrhoeae.
APTIMA COMBO 2 (Hologic Gen-Probe
Incorporated, San Diego,
The United States )
RNA PCR amplification technique for the detection of Chlamydia trachomatis
and/or Neisseria gonorrhoeae
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Finally, the hrHPV assay test can be used on residual
liquid media material importantly in patients, who have
had cervical conization for high grade lesions,67 to deter-
mine hrHPV positive patients who are at risk of recur-
rence after surgery. The hrHPV test can also be used as a
reflex test in cases of cytological atypia of undetermined
significance (ASC-US)68 to improve the detection of high
grade lesions. Liquid media also can be used in the meth-
ylation marker test (CADM1/MAL methylation analysis)
as a triage test in hrHPV positive women in the presence
of CIN2 and CIN3.69
The Use of Liquid Medium for Other Genital
Infections
Many of the microorganisms usually found in cervical–
vaginal region are also detectable in liquid media using
different molecular tests, which are easy to perform and
generate results generally comparable to the traditional,
but generally time consuming, assays such as vaginal
sample cultures or conventional PCR. One of the most
interesting advances are the very robust Chlamydia and
gonorrhea organisms tests, performed in a “combo fash-
ion” system (Table II).
Liquid-based cytology medium samples can be used to
preserve urine similarly to vaginal material for various
tests including the successful identification of the Myco-
plasma genitalium, Mycoplasma hominis, Ureaplasma
parvum, and Ureaplasma urealyticum, in female and male
patients.70 Importantly, in house PCR molecular methods
applied to the residual material from liquid-based cytol-
ogy medium have efficiently recognized Herpes simplex
virus and Cytomegalovirus.71,72
Closing Remarks
The use of molecular methods on cytological material is
a milestone in the specific diagnosis of the ID. The inte-
gration of nucleic acid testing methods with cytopathol-
ogy provides improved diagnostic protocols and in some
cases a correct diagnosis more rapidly for life saving
treatment. However, it is necessary to systematically
assess “which” test to utilize, “where” to use it, and
“how” to integrate the nucleic acid testing methods with
the cytomorphological diagnosis to maximize the diagnos-
tic potential and cost benefit in the challenging diagnosis
of it is. In addition to the classical cytology smear prepa-
ration, the introduction of liquid-based cytology in both
gynecological and non-gynecological investigations has
opened up new horizons in terms of ID diagnoses, pri-
mary screening options, and post-treatment follow-up
methods, demonstrating clear advantages for clinicians
and patients.
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